Sunday, May 5, 2024
Home Biotech News Incubator Page 5

Incubator

    Latest
    Dalarada Health, Biotech Stock Review

    Dalrada Cervical Cancer Testing Kit Study.

    Incubator Editor / Curator -
    KEY TAKEAWAYS Dalrada Corp (DFCO) LIVE QUOTE
    biotech stock review

    Dalrada’s ‘VIA’ Test Screening Kit Goes Head to Head with ‘Pap’ Smear Test Screening.

    Incubator Editor / Curator -
    DALRADA aims to introduce its VIA Test kit to females in India - of which there is 497 million.
    Issam Radd

    Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.

    2020 Watch List Editor / Curator -
    2021 and 2020 Milestones In Plain Sight. Locked and Loaded for most of 2020 - many major milestone...

    Citius Pharma (CTXR) Video Presentation.

    Interview Editor / Curator -
    Chairman Leonard Mazur Discusses: Mino-Lok Treatment for Infected Catheters. Novellus Stem Cell Treatment...

    Mitesco Inc. Initiates “The Good Clinic” Rollout in Minneapolis; Introduces the Founders of “The...

    Telehealth Editor / Curator -
    MINNEAPOLIS, MN, Sept. 14, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Mitesco, Inc. (OTCQB: MITI) today announced that The Good Clinic, LLC has filed...
    American BriVision

    American BriVision’s (ABVC) Clinical Study Sparks Interest From Potential Partners.

    Biotech News Editor / Curator -
    Is Wall Street Missing American Brivision's Full Clinical Safety and Efficacy Study? We Think it has. Potential...

    There’s Simply No Loyalty Anymore.

    Incubator Editor / Curator -
    TODAY'S LETTER Frontier Bio (FBIO) $3.90. We Have Another Double! American BriVision (ABVC) $4.00. Wait, What? Yet...
    Roland Rick Perry, Biotech Stock Review, Frontier Bio

    And We Have Another Double. Frontier Bio (FBIO) Crosses $4.00.

    Biotech News Editor / Curator -
    Sometimes we Can't Beleive Our Luck Over the Last Couple Years. But There You Have it, at Least we Know It's...
    citius pharma, biotech stock review

    Investors Bet $8 Million on Citius Pharma (CTXR) $1.10, Succeeding in FDA Trials!

    2020 Watch List Editor / Curator -
    Great headline, right? The actual headline was: Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million
    American Brivision

    Adding American BriVision (ABVC) $3.30 to Stocks We Expect Double List. $7.00 Price Potential.

    Biotech News Editor / Curator -
    Adding to Our 2020 Biotech 5-Pack, 5 Stocks We Expect to Double in 2020
    1...4567Page 5 of 7

    Latest article

    We’re in Tampa for the Kentucky Derby.

    2024 Watch List Editor / Curator -
    GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

    Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

    Institutional Analyst Newsletter Editor / Curator -
    DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    2024 Watch List Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.